UMass Medical School Developing Lyme disease Vaccine
Lymeblog News October 8, 2015
Lexington, KY USA
By Mac McDonald, MA, CCE
Editor Lymeblog News
New research to be presented at infectious disease conference
IDWeek; Monoclonal antibodies reactive against a broad range of Borrelia
species in studies
Scientists at UMass Medical
School’s MassBiologics are developing a pre-exposure prophylaxis that
prevents tick-transmitted infection of Lyme disease, a breakthrough that
could lead to seasonal prevention against the most common tick-borne
infection in North America.
Scientists at UMass Medical School’s MassBiologics are developing a
pre-exposure prophylaxis that prevents tick-transmitted infection of
Lyme disease, a breakthrough that could lead to seasonal prevention
against the most common tick-borne infection in North America. The
research will be presented on Friday, Oct. 9, in San Diego at IDWeek
2015TM, the annual meeting of the Infectious Disease Society of America,
the Society for Healthcare Epidemiology of America, the HIV Medicine
Association and the Pediatric Infectious Diseases Society. The research
report details the effectiveness of a monoclonal antibody in targeting
the bacteria that causes Lyme disease in mice, the most common natural
reservoir for the bacteria.
“In our strategy, individuals would receive an injection in the
spring of a single human monoclonal antibody targeting a protein on the
surface of the bacteria that would provide immediate protection against
Lyme disease and that protection would last for about 6 months, which is
the risk period when the ticks that transmit Lyme disease are active,”
said Mark S. Klempner, MD, executive vice chancellor of MassBiologics
and professor of medicine at UMMS. “This is the same strategy—a
monoclonal antibody that targets an infectious disease—that is used to
prevent one of the most severe forms of pneumonia in premature infants
called respiratory syncytial virus (RSV). With over 15 years of data
showing the safety and effectiveness of administering this human
monoclonal antibody (Synagis ®) to these most vulnerable babies, we have
observed a very high level of protection with virtually no short or
longer term serious adverse reactions.”
MassBiologics discovers, develops and manufactures biologic medicines
that improve the lives of the people in the Commonwealth of
Massachusetts. As the only non-profit, medical-school-affiliated,
FDA-licensed manufacturer of vaccines and other biologic medicines like
monoclonal antibodies, MassBiologics has a particular focus on public
Lyme disease is the most common tick-borne infection in North
American and Eurasian countries with temperate climates. It is spread
ILADS treatment guidelines now on National Guidelines Clearinghouse
“Exclusion of patient interests and disregard for competing guidelines makes the IDSA review process untrustworthy,”
Dr. Daniel Cameron, President of ILADS and lead author of the ILADS guidelines.
(Bethesda, MD Sept 21, 2015) — The Centers for Disease Control and Prevention (CDC) estimates that more than 300,000 new cases of Lyme disease occur annually in the US.
The International Lyme and Associated Diseases Society (ILADS) has
criticized the Lyme guidelines review panel of the Infectious Diseases
Society of America (IDSA) for excluding patient interests and
disregarding competing guidelines in its review plan.
The ILADS guidelines include share medical decision making and take patient
values into consideration.
Lorraine Johnson, JD, MBA, a coauthor and
Chief Executive Officer of LymeDisease.org, said “A lot of the treatment
decisions in Lyme disease depend on trade-offs. How sick is the
patient, how invasive is the treatment, what is valued by the patient?
Patients need to understand the risks and benefits of treatment options
to make informed medical choices. These guidelines provide that
ILADS is proud to announce their guidelines are now available on the National Guidelines Clearinghouse (NGC) website.
ILADS guidelines, Evidence Assessments and Guideline Recommendations in
Lyme disease: The Clinical Management of Known Tick Bites, Erythema
Migrans Rashes and Persistent Disease” bring the latest scientific
evidence to bear on the management of the illness.
The National Guidelines Clearinghouse (NGC) is an initiative of the Agency for Healthcare Research and Quality (AHRQ), under the umbrella of the U.S. Department of Health and Human Services. The NGC recently adopted the Institute of Medicine (IOM) standards for developing trustworthy guidelines, which define the highest level of excellence that a guideline can achieve. Guidelines posted on the NGC website must now satisfy these standards. Thus, the inclusion of ILADS’s peer reviewed guidelines on the NGC website demonstrates that they meet the ...
Nominate a Doc for NATCAPLYME Scholarship LYME FUNDAMENTALS at ILADS 2015
Deadline for Nominations
Monday, September 7th
NATCAPLYME is pleased to announce a grant program for first time attending physicians to attend the upcoming ILADS Fundamentals of Lyme Disease
Nominate A Local Doctor for the ILADS CME Approved CourseNatCapLyme Scholarships Available
The National Capital Lyme and Tick-Borne
Disease Association strives to improve the quality of care for those
suffering from tick-borne illnesses by offering educational
opportunities for local health care professionals.
To advance this objective NatCapLyme will offer scholarships for medical professionals to this important CME approved course.
The Fundamentals of Diagnosing and Treating Tick-Borne Illness
course targets medical professionals who are new to treating patients
with tick borne infections, or would like a refresher course on the
fundamentals of diagnosis and treatment. This course is also an
excellent primer for nurse practitioners and physician assistants who
are practicing in the offices of Lyme literate physicians
APPLY TO NatCapLyme by e-mail to NatCapLyme@natcaplyme.org or call 703-821-8833The Deadline for your nomination isMonday, September 7th
By 2009 Angeli VanLaanenhad won 7 medals in halfpipe and slopestyle ski competitions. She had only been competing for 4 years but the fatigue and confusion she had been living with since she was a child finally became too much to "just push through". She thought everybody felt this way but events like falling asleep on a ski lift made her finally step back and seek an answer to her myriad symptoms. At age 24 she was just too tired to get out of bed, let alone compete in world class freestyle skiing events.
That is when VanLaanen took a three-year break from halfpipe skiing to treat Lyme disease, which had gone misdiagnosed for 14 years.
After 3 years of treatment and a complete change in lifestyle she came back to competitive skiing and took 2nd place in North Face Open Halfpipe, New Zealand, 2012. She kept on competing and in 2014 was a member of the U.S. Olympic Team in Sochi, Russia.
On May 13, 2015 30 year old Angeli VanLaanen announced her "official retirement from Competitive Halfpipe Skiing" on Facebook. She still skis and is an avid supporter of the Lymelight Foundation a charity whose mission is to provide grants to enable
eligible children and young adults with Lyme disease to receive proper
treatment and medication as well as raising awareness about Lyme
"Lymelight" is a 30 minute film by John Roderick of Neu Productions is a Lyme Disease awareness film that "serves as an inspirational story for those who have fought to overcome chronic illness and ...
Video: Avril Lavigne opens up about Lyme disease battle
Lymeblog News June 29, 2015
Lexington, KY USA
By Mac McDonald, MA, CCE
Editor Lymeblog News
Avril Lavigne opens up about Lyme disease battle on Good Morning America
“They would pull up their computer and be like, ‘Chronic fatigue syndrome.’ Or, ‘Why don't you try to get out of bed, Avril, and just go play the piano?’ It's like, ‘Are you depressed?’”
“I'm about halfway through my treatment,” the Canadian singer said in an interview with ABC News’ Jesse Palmer. "I'm doing a lot better. Seeing a lot of progress. ... I'm just really grateful to know that, like, I will make [a] 100 percent recovery."
After being misdiagnosed, bedridden for 5 months, told it was all in her head, and improperly treated Lavigne found a specialist who istreating her with a regime that includes antibiotics and lots of rest.
“There is hope. Lyme disease does exist. And ...
FAIR USE NOTICE: This page may contain copyrighted material the use of which has not been specifically authorized by the copyright owner. This website distributes this material without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. We believe this constitutes a fair use of any such copyrighted material as provided for in 17 U.S.C § 107.
NOTE TO AUTHORS: If you are the author of this article and do not wish to have this article printed on the LymeBlog website, please write to us and we will remove the article.
Disclaimer: No warranties are provided either explicitly or implicitly as to the validity of any information herein. URLville Web Services does not take responsibility for the accuracy of any information and suggests that you do your own research and consult your doctor before making any treatment decisions.
URLville Web Services is not responsible for any third-party information referred to from the site. URLville Web Services may make a small referral fee for products you purchase from links within this site. URLville Web Services is not responsible for information or products found through sites referred by stories or ads on this website.